Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 49

1.

A research agenda for malaria eradication: vector control.

malERA Consultative Group on Vector Control.

PLoS Med. 2011 Jan 25;8(1):e1000401. doi: 10.1371/journal.pmed.1000401. Review.

2.

A research agenda for malaria eradication: basic science and enabling technologies.

malERA Consultative Group on Basic Science and Enabling Technologies.

PLoS Med. 2011 Jan 25;8(1):e1000399. doi: 10.1371/journal.pmed.1000399. Review. Erratum in: PLoS Med. 2011 May;8(5).doi: 10.1371/annotation/e6a85761-7a23-435a-97df-f13c1ba4e8da. Gilberger, Tim [added].

3.

A research agenda for malaria eradication: diagnoses and diagnostics.

malERA Consultative Group on Diagnoses and Diagnostics.

PLoS Med. 2011 Jan 25;8(1):e1000396. doi: 10.1371/journal.pmed.1000396. Review.

4.

The role of research in viral disease eradication and elimination programs: lessons for malaria eradication.

Breman JG, de Quadros CA, Dowdle WR, Foege WH, Henderson DA, John TJ, Levine MM.

PLoS Med. 2011 Jan 25;8(1):e1000405. doi: 10.1371/journal.pmed.1000405. Review.

5.

A research agenda for malaria eradication: monitoring, evaluation, and surveillance.

malERA Consultative Group on Monitoring, Evaluation, and Surveillance.

PLoS Med. 2011 Jan 25;8(1):e1000400. doi: 10.1371/journal.pmed.1000400. Review.

6.

A research agenda for malaria eradication: drugs.

malERA Consultative Group on Drugs.

PLoS Med. 2011 Jan 25;8(1):e1000402. doi: 10.1371/journal.pmed.1000402. Review.

7.

A research agenda for malaria eradication: modeling.

malERA Consultative Group on Modeling.

PLoS Med. 2011 Jan 25;8(1):e1000403. doi: 10.1371/journal.pmed.1000403. Review.

8.

A research agenda for malaria eradication: cross-cutting issues for eradication.

malERA Consultative Group on Integration Strategies.

PLoS Med. 2011 Jan 25;8(1):e1000404. doi: 10.1371/journal.pmed.1000404. Review.

9.

Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria.

Hoffman SL, Billingsley PF, James E, Richman A, Loyevsky M, Li T, Chakravarty S, Gunasekera A, Chattopadhyay R, Li M, Stafford R, Ahumada A, Epstein JE, Sedegah M, Reyes S, Richie TL, Lyke KE, Edelman R, Laurens MB, Plowe CV, Sim BK.

Hum Vaccin. 2010 Jan;6(1):97-106. Epub 2010 Jan 21. Review.

PMID:
19946222
10.

Genetic diversity and malaria vaccine design, testing and efficacy: preventing and overcoming 'vaccine resistant malaria'.

Takala SL, Plowe CV.

Parasite Immunol. 2009 Sep;31(9):560-73. doi: 10.1111/j.1365-3024.2009.01138.x. Review.

11.

A potent malaria transmission blocking vaccine based on codon harmonized full length Pfs48/45 expressed in Escherichia coli.

Chowdhury DR, Angov E, Kariuki T, Kumar N.

PLoS One. 2009 Jul 22;4(7):e6352. doi: 10.1371/journal.pone.0006352.

12.

New developments in Plasmodium vivax malaria: severe disease and the rise of chloroquine resistance.

Price RN, Douglas NM, Anstey NM.

Curr Opin Infect Dis. 2009 Oct;22(5):430-5. doi: 10.1097/QCO.0b013e32832f14c1. Review.

PMID:
19571748
13.

Plasmodium knowlesi from archival blood films: further evidence that human infections are widely distributed and not newly emergent in Malaysian Borneo.

Lee KS, Cox-Singh J, Brooke G, Matusop A, Singh B.

Int J Parasitol. 2009 Aug;39(10):1125-8. doi: 10.1016/j.ijpara.2009.03.003. Epub 2009 Apr 7.

14.

Severe Plasmodium vivax malaria: a report on serial cases from Bikaner in northwestern India.

Kochar DK, Das A, Kochar SK, Saxena V, Sirohi P, Garg S, Kochar A, Khatri MP, Gupta V.

Am J Trop Med Hyg. 2009 Feb;80(2):194-8.

PMID:
19190212
15.

Role of injectable and oral polio vaccines in polio eradication.

John J.

Expert Rev Vaccines. 2009 Jan;8(1):5-8. doi: 10.1586/14760584.8.1.5. Review. No abstract available.

PMID:
19093765
16.

Effect of a fall in malaria transmission on morbidity and mortality in Kilifi, Kenya.

O'Meara WP, Bejon P, Mwangi TW, Okiro EA, Peshu N, Snow RW, Newton CR, Marsh K.

Lancet. 2008 Nov 1;372(9649):1555-62. doi: 10.1016/S0140-6736(08)61655-4.

17.

Changes in malaria indices between 1999 and 2007 in The Gambia: a retrospective analysis.

Ceesay SJ, Casals-Pascual C, Erskine J, Anya SE, Duah NO, Fulford AJ, Sesay SS, Abubakar I, Dunyo S, Sey O, Palmer A, Fofana M, Corrah T, Bojang KA, Whittle HC, Greenwood BM, Conway DJ.

Lancet. 2008 Nov 1;372(9649):1545-54. doi: 10.1016/S0140-6736(08)61654-2.

18.

What should vaccine developers ask? Simulation of the effectiveness of malaria vaccines.

Penny MA, Maire N, Studer A, Schapira A, Smith TA.

PLoS One. 2008 Sep 11;3(9):e3193. doi: 10.1371/journal.pone.0003193.

19.

Effective induction of high-titer antibodies by viral vector vaccines.

Draper SJ, Moore AC, Goodman AL, Long CA, Holder AA, Gilbert SC, Hill F, Hill AV.

Nat Med. 2008 Aug;14(8):819-21. doi: 10.1038/nm.1850. Epub 2008 Jul 27.

20.

Antibodies targeting the PfRH1 binding domain inhibit invasion of Plasmodium falciparum merozoites.

Gao X, Yeo KP, Aw SS, Kuss C, Iyer JK, Genesan S, Rajamanonmani R, Lescar J, Bozdech Z, Preiser PR.

PLoS Pathog. 2008 Jul 11;4(7):e1000104. doi: 10.1371/journal.ppat.1000104.

Supplemental Content

Support Center